Cargando…
A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188817/ https://www.ncbi.nlm.nih.gov/pubmed/35667483 http://dx.doi.org/10.1016/j.jinf.2022.06.001 |
| _version_ | 1784725459889553408 |
|---|---|
| author | Lv, Panjing Hu, Bing Hua, Rong Zhang, Jun Zhang, Haoran Liu, Zhang Xu, Liqiong He, Zhen Li, Xiang Guo, Ming Pan, Kai Zhang, Zhen Zeng, Qili Wu, Zhi Sun, Li Guo, Meng Zhou, Li Xu, Xiuzhen Yu, Bo Xu, Junqiang Yuan, Shuai Guo, Min Cai, Kun Xia, Yuchen Li, Yan |
| author_facet | Lv, Panjing Hu, Bing Hua, Rong Zhang, Jun Zhang, Haoran Liu, Zhang Xu, Liqiong He, Zhen Li, Xiang Guo, Ming Pan, Kai Zhang, Zhen Zeng, Qili Wu, Zhi Sun, Li Guo, Meng Zhou, Li Xu, Xiuzhen Yu, Bo Xu, Junqiang Yuan, Shuai Guo, Min Cai, Kun Xia, Yuchen Li, Yan |
| author_sort | Lv, Panjing |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9188817 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The British Infection Association. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91888172022-06-13 A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern Lv, Panjing Hu, Bing Hua, Rong Zhang, Jun Zhang, Haoran Liu, Zhang Xu, Liqiong He, Zhen Li, Xiang Guo, Ming Pan, Kai Zhang, Zhen Zeng, Qili Wu, Zhi Sun, Li Guo, Meng Zhou, Li Xu, Xiuzhen Yu, Bo Xu, Junqiang Yuan, Shuai Guo, Min Cai, Kun Xia, Yuchen Li, Yan J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-09 2022-06-03 /pmc/articles/PMC9188817/ /pubmed/35667483 http://dx.doi.org/10.1016/j.jinf.2022.06.001 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Lv, Panjing Hu, Bing Hua, Rong Zhang, Jun Zhang, Haoran Liu, Zhang Xu, Liqiong He, Zhen Li, Xiang Guo, Ming Pan, Kai Zhang, Zhen Zeng, Qili Wu, Zhi Sun, Li Guo, Meng Zhou, Li Xu, Xiuzhen Yu, Bo Xu, Junqiang Yuan, Shuai Guo, Min Cai, Kun Xia, Yuchen Li, Yan A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern |
| title | A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern |
| title_full | A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern |
| title_fullStr | A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern |
| title_full_unstemmed | A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern |
| title_short | A novelly designed protein antagonist confers potent neutralization against SARS-CoV-2 variants of concern |
| title_sort | novelly designed protein antagonist confers potent neutralization against sars-cov-2 variants of concern |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188817/ https://www.ncbi.nlm.nih.gov/pubmed/35667483 http://dx.doi.org/10.1016/j.jinf.2022.06.001 |
| work_keys_str_mv | AT lvpanjing anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT hubing anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT huarong anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhangjun anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhanghaoran anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT liuzhang anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xuliqiong anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT hezhen anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT lixiang anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT guoming anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT pankai anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhangzhen anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zengqili anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT wuzhi anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT sunli anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT guomeng anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhouli anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xuxiuzhen anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT yubo anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xujunqiang anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT yuanshuai anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT guomin anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT caikun anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xiayuchen anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT liyan anovellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT lvpanjing novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT hubing novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT huarong novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhangjun novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhanghaoran novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT liuzhang novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xuliqiong novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT hezhen novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT lixiang novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT guoming novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT pankai novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhangzhen novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zengqili novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT wuzhi novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT sunli novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT guomeng novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT zhouli novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xuxiuzhen novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT yubo novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xujunqiang novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT yuanshuai novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT guomin novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT caikun novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT xiayuchen novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern AT liyan novellydesignedproteinantagonistconferspotentneutralizationagainstsarscov2variantsofconcern |